A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for Hepatocellular Carcinoma.

Edeline, J; Blanc, J; Johnson, P; Campillo-Gimenez, B; Ross, P; Ma, Y; King, J; Hubner, Richard A; Sumpter, K; Darby, S; Evans, J; Iwuji, C; Swinson, D; Collins, P; Patel, K; Muazzam, I; Palmer, D; Meyer, T

Affiliation

Centre Eugene Marquis, Rennes, France

Issue Date

2016-05-23

Metadata

Show full item record

Abstract

The ALBI grade was proposed as an objective means to evaluate liver function in patients with Hepatocellular Carcinoma (HCC). ALBI grade 1 vs 2 were proposed as stratification factors within the Child Pugh (CP) A class. However, the original publication did not provide comparison with the sub-classification by points (5 to 15) within the CP classification.

Citation

A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for Hepatocellular Carcinoma. 2016: Liver Int

Journal

Liver International

URI

http://hdl.handle.net/10541/613309

DOI

10.1111/liv.13170

PubMed ID

27214151

Type

Article

Language

ISSN

1478-3231

Collections

All Christie Publications